UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
- UK Biobank (Lead Research Organisation)
- AbbVie Inc (Collaboration)
- AstraZeneca (Collaboration)
- Alnylam Pharmaceuticals (Collaboration)
- Regeneron Pharmaceuticals, Inc. (Collaboration)
- Pfizer Inc (Collaboration)
- Takeda Pharmaceutical Company (Collaboration)
- Bristol-Myers Squibb (Collaboration)
- Biogen Idec (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
People |
ORCID iD |
| Rory Collins (Principal Investigator) |
Publications
Raisi-Estabragh Z
(2022)
Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank.
in Heart (British Cardiac Society)
Raisi-Estabragh Z
(2023)
Lower birth weight is linked to poorer cardiovascular health in middle-aged population-based adults.
in Heart (British Cardiac Society)
Raisi-Estabragh Z
(2020)
Age, sex and disease-specific associations between resting heart rate and cardiovascular mortality in the UK BIOBANK.
in PloS one
Raisi-Estabragh Z
(2022)
Left atrial structure and function are associated with cardiovascular outcomes independent of left ventricular measures: a UK Biobank CMR study.
in European heart journal. Cardiovascular Imaging
Raisi-Estabragh Z
(2021)
Cardiovascular magnetic resonance imaging in the UK Biobank: a major international health research resource.
in European heart journal. Cardiovascular Imaging
Raisi-Estabragh Z
(2021)
Poor Bone Quality is Associated With Greater Arterial Stiffness: Insights From the UK Biobank.
in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Raisi-Estabragh Z
(2023)
Incident Clinical and Mortality Associations of Myocardial Native T1 in the UK Biobank.
in JACC. Cardiovascular imaging
Raisi-Estabragh Z
(2020)
Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank.
in Journal of public health (Oxford, England)
Raisi-Estabragh Z
(2021)
Cardiac Magnetic Resonance Radiomics Reveal Differential Impact of Sex, Age, and Vascular Risk Factors on Cardiac Structure and Myocardial Tissue
in Frontiers in Cardiovascular Medicine
Raisi-Estabragh Z
(2022)
Estimation of biological heart age using cardiovascular magnetic resonance radiomics.
in Scientific reports
Raisi-Estabragh Z
(2022)
Associations of cognitive performance with cardiovascular magnetic resonance phenotypes in the UK Biobank.
in European heart journal. Cardiovascular Imaging
Raisi-Estabragh Z
(2021)
Associations of Meat and Fish Consumption With Conventional and Radiomics Cardiovascular Magnetic Resonance Phenotypes in the UK Biobank
in Frontiers in Cardiovascular Medicine
Raisi-Estabragh Z
(2023)
Response to: Correspondence on 'Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank' by Jolobe.
in Heart (British Cardiac Society)
Raisi-Estabragh Z
(2022)
Corrigendum to: Left atrial structure and function are associated with cardiovascular outcomes independent of left ventricular measures: a UK Biobank CMR study.
in European heart journal. Cardiovascular Imaging
Raisi-Estabragh Z
(2021)
Adverse cardiovascular magnetic resonance phenotypes are associated with greater likelihood of incident coronavirus disease 2019: findings from the UK Biobank.
in Aging clinical and experimental research
Rait G
(2020)
Twenty-year sociodemographic trends in lung cancer in non-smokers: A UK-based cohort study of 3.7 million people.
in Cancer epidemiology
Raita Y
(2021)
Relationship of Soluble Interleukin-6 Receptors With Asthma: A Mendelian Randomization Study.
in Frontiers in medicine
Ramachandran AK
(2024)
Relation between Apolipoprotein E in Alzheimer's Disease and SARS-CoV-2 and their Treatment Strategy: A Review.
in CNS & neurological disorders drug targets
Ramadan FA
(2022)
Association of sedentary and physical activity behaviours with body composition: a genome-wide association and Mendelian randomisation study.
in BMJ open sport & exercise medicine
Ramakrishnan R
(2021)
Accelerometer measured physical activity and the incidence of cardiovascular disease: Evidence from the UK Biobank cohort study.
in PLoS medicine
Ramírez J
(2018)
Thirty loci identified for heart rate response to exercise and recovery implicate autonomic nervous system.
in Nature communications
Ramírez J
(2019)
Cardiovascular Predictive Value and Genetic Basis of Ventricular Repolarization Dynamics.
in Circulation. Arrhythmia and electrophysiology
Ramírez J
(2022)
ECG T-Wave Morphologic Variations Predict Ventricular Arrhythmic Risk in Low- and Moderate-Risk Populations.
in Journal of the American Heart Association
Ramírez J
(2022)
Prediction of Coronary Artery Disease and Major Adverse Cardiovascular Events Using Clinical and Genetic Risk Scores for Cardiovascular Risk Factors.
in Circulation. Genomic and precision medicine
Ramírez J
(2021)
Analysing electrocardiographic traits and predicting cardiac risk in UK biobank.
in JRSM cardiovascular disease
Ran S
(2020)
Whole-exome sequencing and genome-wide association studies identify novel sarcopenia risk genes in Han Chinese.
in Molecular genetics & genomic medicine
Rannikmäe K
(2021)
Developing automated methods for disease subtyping in UK Biobank: an exemplar study on stroke
in BMC Medical Informatics and Decision Making
Rannikmäe K
(2020)
Accuracy of identifying incident stroke cases from linked health care data in UK Biobank.
in Neurology
Rao AS
(2018)
Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke.
in Circulation. Genomic and precision medicine
Rasheed H
(2021)
The causal effects of serum lipids and apolipoproteins on kidney function: multivariable and bidirectional Mendelian-randomization analyses.
in International journal of epidemiology
Rask-Andersen M
(2021)
Modification of Heritability for Educational Attainment and Fluid Intelligence by Socioeconomic Deprivation in the UK Biobank.
in The American journal of psychiatry
Rask-Andersen M
(2019)
Genome-wide association study of body fat distribution identifies adiposity loci and sex-specific genetic effects.
in Nature communications
Rasnic R
(2020)
Expanding cancer predisposition genes with ultra-rare cancer-exclusive human variations.
in Scientific reports
Rastogi T
(2022)
Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from HOMAGE and the UK Biobank.
in European journal of heart failure
Rauber F
(2021)
Ultra-processed food consumption and risk of obesity: a prospective cohort study of UK Biobank.
in European journal of nutrition
Rauseo E
(2021)
New Imaging Signatures of Cardiac Alterations in Ischaemic Heart Disease and Cerebrovascular Disease Using CMR Radiomics.
in Frontiers in cardiovascular medicine
Ravera S
(2018)
Phenomic Impact of Genetically-Determined Euthyroid Function and Molecular Differences between Thyroid Disorders.
in Journal of clinical medicine
Rawlik K
(2019)
Indirect assortative mating for human disease and longevity.
in Heredity
Rayner C
(2019)
Genetic influences on treatment-seeking for common mental health problems in the UK biobank.
in Behaviour research and therapy
Razban R
(2022)
Early Path Dominance as a Principle for Neurodevelopment
Razieh C
(2021)
Ethnic minorities and COVID-19: examining whether excess risk is mediated through deprivation.
in European journal of public health
Razieh C
(2020)
Body mass index and the risk of COVID-19 across ethnic groups: Analysis of UK Biobank.
in Diabetes, obesity & metabolism
Razieh C
(2022)
Differences in the risk of cardiovascular disease across ethnic groups: UK Biobank observational study.
in Nutrition, metabolism, and cardiovascular diseases : NMCD
Re F
(2021)
Effects of Within-Person Variability in Spot Urinary Sodium Measurements on Associations With Blood Pressure and Cardiovascular Disease.
in Hypertension (Dallas, Tex. : 1979)
Read RW
(2021)
Genome-Wide Identification of Rare and Common Variants Driving Triglyceride Levels in a Nevada Population.
in Frontiers in genetics
Reay WR
(2022)
Genetics-informed precision treatment formulation in schizophrenia and bipolar disorder.
in American journal of human genetics
Reay WR
(2022)
The genetic architecture of pneumonia susceptibility implicates mucin biology and a relationship with psychiatric illness.
in Nature communications
| Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
| Amount | £2,474,260 (GBP) |
| Funding ID | RG/18/6/33576 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2019 |
| End | 06/2024 |
| Description | UK Biobank - Data Analytics Platform |
| Amount | £20,000,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 01/2023 |
| Description | UK Biobank - The Repeat Imaging Project |
| Amount | £2,500,000 (GBP) |
| Funding ID | R39738/CN039 |
| Organisation | MRC Dementias Platform UK |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 01/2023 |
| Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
| Amount | £30,000,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 03/2020 |
| Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
| Amount | £8,500,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 12/2022 |
| Description | Biobank Enhancement |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | exome sequencing of 50,000 participants |
| Collaborator Contribution | creating vast amounts of genetic data to be used by researchers accessing UKBiobank |
| Impact | exome data |
| Start Year | 2017 |
| Description | Biobank Enhancement |
| Organisation | Regeneron Pharmaceuticals, Inc. |
| Country | United States |
| Sector | Private |
| PI Contribution | exome sequencing of 50,000 participants |
| Collaborator Contribution | creating vast amounts of genetic data to be used by researchers accessing UKBiobank |
| Impact | exome data |
| Start Year | 2017 |
| Description | Genetic enhancement |
| Organisation | AbbVie Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants |
| Collaborator Contribution | The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines. |
| Impact | The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use. |
| Start Year | 2018 |
| Description | Genetic enhancement |
| Organisation | Alnylam Pharmaceuticals |
| Country | United States |
| Sector | Private |
| PI Contribution | Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants |
| Collaborator Contribution | The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines. |
| Impact | The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use. |
| Start Year | 2018 |
| Description | Genetic enhancement |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants |
| Collaborator Contribution | The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines. |
| Impact | The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use. |
| Start Year | 2018 |
| Description | Genetic enhancement |
| Organisation | Biogen Idec |
| Country | United States |
| Sector | Private |
| PI Contribution | Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants |
| Collaborator Contribution | The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines. |
| Impact | The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use. |
| Start Year | 2018 |
| Description | Genetic enhancement |
| Organisation | Bristol-Myers Squibb |
| Country | United States |
| Sector | Private |
| PI Contribution | Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants |
| Collaborator Contribution | The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines. |
| Impact | The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use. |
| Start Year | 2018 |
| Description | Genetic enhancement |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants |
| Collaborator Contribution | The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines. |
| Impact | The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use. |
| Start Year | 2018 |
| Description | Genetic enhancement |
| Organisation | Pfizer Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants |
| Collaborator Contribution | The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines. |
| Impact | The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use. |
| Start Year | 2018 |
| Description | Genetic enhancement |
| Organisation | Regeneron Pharmaceuticals, Inc. |
| Country | United States |
| Sector | Private |
| PI Contribution | Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants |
| Collaborator Contribution | The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines. |
| Impact | The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use. |
| Start Year | 2018 |
| Description | Genetic enhancement |
| Organisation | Takeda Pharmaceutical Company |
| Department | Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) |
| Country | United States |
| Sector | Private |
| PI Contribution | Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants |
| Collaborator Contribution | The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines. |
| Impact | The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use. |
| Start Year | 2018 |
| Description | UK Biobank GP linkage |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | UK Biobank event for the General Practice Data for Planing and Research programme (GP linkage). 1,200 attendees |
| Year(s) Of Engagement Activity | 2021 |
| Description | UK Biobank Scientific Conference |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
| Year(s) Of Engagement Activity | 2018 |
| Description | UK Biobank Scientific Conference 2021 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The UK Biobank Scientific Conference in 2021 had 3,000 participants from the research community, professional practitioners, media, study particiapnts and other partners. |
| Year(s) Of Engagement Activity | 2021 |
| Description | UK Biobank participant imaging event |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | UK Biobank for participants of the imaging work |
| Year(s) Of Engagement Activity | 2021 |
| Description | UKBiobank participant events - 2014 - 2019 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
| Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
| URL | http://www.ukbiobank.ac.uk |